Risk of Anemia Development and Clinical Effects of Oral Iron Therapy in Women (18-55 Years) With Non-Anemic Iron Deficiency
This study investigates the risk of anemia development in women aged 18-55 years with non-anemic iron deficiency and evaluates the clinical effects of oral iron therapy. The study consists of a two-month nutritional intervention phase followed by a one-month oral iron treatment phase. Participants first receive dietary counseling aimed at increasing iron intake and absorption. After two months, changes in hematologic parameters and symptoms are evaluated. Women with persistent iron deficiency then receive daily oral ferrous sulfate (80 mg elemental iron) for one month. The study aims to identify early predictors of anemia progression and to assess the impact of dietary modification and oral iron therapy on symptoms and laboratory findings.
• Female participants aged 18-55 years (including premenopausal and menopausal women).
• Normal hemoglobin level (≥ 12 g/dL).
• Serum ferritin \< 15 μg/L (WHO criteria for iron deficiency).
• Mentzer index \> 13.
• Normal levels of vitamin B12, folic acid, thyroid hormones (TSH and sT4), and C-reactive protein (CRP \< 5 mg/L).
• Non-anemic iron deficiency confirmed by laboratory results.
• Good general health and cognitive capacity to provide informed consent.
• Willingness to participate, comply with study procedures, and provide written informed consent.